trending Market Intelligence /marketintelligence/en/news-insights/trending/MXd31NClDPCxCo_d4dhhYA2 content esgSubNav
In This List

Akari Therapeutics prices $17.4M offering

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet

Blog

Insight Weekly: Stocks limp into 2023; GCC banks set for rebound; deep-sea mining faces pushback

Infographic

Infographic: The Big Picture 2023 Sustainability Outlook

Blog

The Big Picture for 2023: Assessing Investment Trends and the Impact of Investor Activism


Akari Therapeutics prices $17.4M offering

Akari Therapeutics PLC priced an underwritten public offering of 3,480,000 American depositary shares at $5 apiece to raise $17.4 million in gross proceeds.

The company also granted underwriters a 30-day option to buy up to an additional 522,000 of the ADSs offered.

Akari plans to use funds raised for general corporate purposes.

The offering is expected to close by Oct. 20 with Cantor Fitzgerald & Co., William Blair & Co. LLC and Canaccord Genuity Inc. acting as joint book-running managers.